<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298909</url>
  </required_header>
  <id_info>
    <org_study_id>Leipzig-02</org_study_id>
    <nct_id>NCT00298909</nct_id>
  </id_info>
  <brief_title>Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)</brief_title>
  <official_title>Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <brief_summary>
    <textblock>
      The investigators want to study the relative effects of physical exercise vs.
      extended-release niacin (lipid-lowering drug) in patients with coronary heart disease and low
      HDL cholesterol (&quot;good cholesterol&quot;) on

        -  lipid profile

        -  endothelial function as measured by ultrasound

      The endothelium is the inner part of the blood vessels. Impaired endothelial function is
      known to be associated with atherosclerosis which can ultimately lead to diseases such as
      stroke, heart attack and others. Endothelial function can be assessed non-invasively by
      ultrasound.

      Both interventions mentioned above have been shown to have a beneficial effect on lipid
      profile and endothelial function. However, the relative effects are unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of physical exercise vs. extended-release niacin in patients with CAD and low HDL
      cholesterol (&lt; 1,03 mmol/L) on lipid profile and endothelial function as measured by
      flow-mediated dilatation of radial artery. Secondary goals are the assessment of biochemical
      markers of atherosclerosis, expression of monocyte surface markers, oxidative stress and
      thrombogenicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative effect on flow-mediated dilatation of radial artery</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical markers of atherosclerosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of monocyte surface markers</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombogenicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Hypolipoproteinemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>niacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>physical exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>physical exercise</intervention_name>
    <description>physical exercise</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niaspan (extended-release niacin)</intervention_name>
    <description>niaspan (extended-release niacin)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin</intervention_name>
    <description>niacin extended-release</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>control</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary disease

          -  Low HDL cholesterol

          -  Age limits (see below)

        Exclusion Criteria:

          -  Unstable angina oder MI within 3 months prior to inclusion

          -  CAD with indication for bypass surgery

          -  Left main disease ( &gt; 25% stenosis diameter)

          -  Ejection fraction &lt; 40%

          -  Higher degree heart valve disease

          -  Higher degree ventricular arrhythmias

          -  Type 1 Diabetes

          -  Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)&gt;
             5.0 mmol/L)

          -  Severe liver disease

          -  Thyroid disease

          -  Alcohol or drug abuse

          -  Pregnancy

          -  Stroke or Transient Ischemic Attack (TIA) within 3 months prior to inclusion

          -  Allergy against niacin oder other ingredient of niaspan

          -  Participation in other clinical trial within 30 days prior to inclusion

          -  Acute gastric ulcer

          -  Arterial bleeding

          -  Uncontrolled severe arterial hypertension

          -  Treatment with lipid-lowering drug other than Hydroxy-Methylglutaryl Coenzyme A
             (HMG-CoA)-inhibitor within 3 months prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Desch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>July 29, 2012</last_update_submitted>
  <last_update_submitted_qc>July 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Steffen Desch, MD</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Hypolipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

